Last reviewed · How we verify

PF-05221304 — Competitive Intelligence Brief

PF-05221304 (pf-05221304) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetyl-CoA carboxylase inhibitor. Area: Infectious Disease.

discontinued Acetyl-CoA carboxylase inhibitor Acetyl-CoA carboxylase (ACC1 and ACC2) Infectious Disease Live · refreshed every 30 min

Target snapshot

PF-05221304 (pf-05221304) — Pfizer Inc.. Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PF-05221304 TARGET pf-05221304 Pfizer Inc. discontinued Acetyl-CoA carboxylase inhibitor Acetyl-CoA carboxylase (ACC1 and ACC2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Acetyl-CoA carboxylase inhibitor class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-05221304 — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-05221304. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: